← Back to Screener
Takeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) (TAK)
Price$17.55
Favorite Metrics
Price vs S&P 500 (26W)19.09%
Price vs S&P 500 (4W)-11.05%
Market Capitalization$55.76B
P/E Ratio (Annual)82.04x
Indicated Dividend Yield (Annual)3.59%
All Metrics
P/CF (Annual)8.38x
Book Value / Share (Quarterly)$30.47
P/TBV (Annual)2.13x
Indicated Dividend (Annual)$1.26
Revenue Growth (3Y)8.68%
Cash Flow / Share (Quarterly)$2.98
Payout Ratio (TTM)129.16%
Price vs S&P 500 (YTD)11.36%
Gross Margin (TTM)65.33%
Net Profit Margin (TTM)2.53%
EPS (TTM)$0.46
10-Day Avg Trading Volume4.18M
EPS Excl Extra (TTM)$0.46
Revenue Growth (5Y)6.84%
EPS (Annual)$0.43
Dividend / Share (Annual)$1.21
ROI (Annual)0.94%
Gross Margin (Annual)65.51%
Net Profit Margin (5Y Avg)6.36%
Cash / Share (Quarterly)$3.04
P/E Basic Excl Extra (TTM)78.41x
Revenue Growth QoQ (YoY)4.16%
EPS Growth (5Y)19.33%
P/E Normalized (Annual)82.04x
ROA (Last FY)0.76%
Revenue Growth TTM (YoY)-2.50%
EBITD / Share (TTM)$3.58
ROE (5Y Avg)3.97%
Operating Margin (TTM)7.78%
Cash Flow / Share (Annual)$2.84
P/B Ratio1.16x
P/B Ratio (Quarterly)1.00x
Net Income / Employee (Annual)$0
EV / Revenue (TTM)2.92x
Net Interest Coverage (TTM)1.96x
ROA (TTM)0.78%
EPS Growth QoQ (YoY)337.18%
EV / EBITDA (TTM)14.57x
EPS Incl Extra (Annual)$0.43
Current Ratio (Annual)1.01x
Quick Ratio (Quarterly)0.65x
3-Month Avg Trading Volume4.85M
52-Week Price Return5.51%
EV / Free Cash Flow (Annual)18.40x
P/E Incl Extra (TTM)78.41x
Revenue / Employee (TTM)$1
Tangible BV / Share (Quarterly)$16.45
P/S Ratio (Annual)1.93x
Asset Turnover (Annual)0.32x
52-Week High$6033.00
Operating Margin (5Y Avg)11.63%
EPS Excl Extra (Annual)$0.43
CapEx CAGR (5Y)9.82%
Tangible BV CAGR (5Y)43.02%
26-Week Price Return27.84%
Quick Ratio (Annual)0.52x
13-Week Price Return7.71%
Total Debt / Equity (Annual)0.65x
Current Ratio (Quarterly)1.19x
Enterprise Value$82,201.776
Revenue / Share Growth (5Y)6.67%
Asset Turnover (TTM)0.31x
Book Value / Share Growth (5Y)7.76%
Revenue / Employee (Annual)$1
Inventory Turnover (Annual)1.30x
Pretax Margin (Annual)3.82%
Cash / Share (Annual)$1.62
3-Month Return Std Dev23.18%
Gross Margin (5Y Avg)67.81%
Net Income / Employee (TTM)$0
EBITDA CAGR (5Y)10.36%
EBITDA Interim CAGR (5Y)4.68%
ROE (Last FY)1.56%
Net Interest Coverage (Annual)2.45x
EPS Basic Excl Extra (Annual)$0.43
P/FCF (TTM)11.83x
Receivables Turnover (TTM)6.17x
EV / Free Cash Flow (TTM)17.43x
Total Debt / Equity (Quarterly)0.64x
EPS Incl Extra (TTM)$0.46
Receivables Turnover (Annual)7.25x
ROI (TTM)0.96%
Dividend Growth Rate (5Y)1.18%
P/S Ratio (TTM)1.98x
Pretax Margin (5Y Avg)6.86%
Revenue / Share (Annual)$18.27
Tangible BV / Share (Annual)$13.22
Forward P/E38.86x
Free OCF CAGR (5Y)9.40%
Price vs S&P 500 (52W)-12.10%
P/E Ratio (TTM)78.41x
EPS Growth TTM (YoY)-44.51%
Year-to-Date Return15.31%
5-Day Price Return-0.52%
EPS Normalized (Annual)$0.43
ROA (5Y Avg)1.73%
Net Profit Margin (Annual)2.36%
Month-to-Date Return-1.57%
Cash Flow / Share (TTM)$3.54
EBITD / Share (Annual)$3.61
EPS Growth (3Y)-22.33%
Operating Margin (Annual)7.79%
LT Debt / Equity (Annual)0.57x
P/CF (TTM)7.45x
ROI (5Y Avg)2.24%
P/E Excl Extra (TTM)78.41x
LT Debt / Equity (Quarterly)0.56x
EPS Basic Excl Extra (TTM)$0.46
P/TBV (Quarterly)1.86x
Payout Ratio (Annual)280.28%
P/B Ratio (Annual)1.01x
Dividend / Share (TTM)$1.25
Inventory Turnover (TTM)1.17x
Pretax Margin (TTM)4.60%
Book Value / Share (Annual)$27.75
Price vs S&P 500 (13W)4.84%
Net Margin Growth (5Y)11.99%
Dividend Yield (TTM)3.53%
Beta0.39x
P/FCF (Annual)12.48x
Revenue / Share (TTM)$17.81
ROE (TTM)1.58%
52-Week Low$4000.00
Industry Peers — Pharmaceuticals(308)
| Symbol | P/S Ratio (TTM) | Revenue Growth TTM (YoY) | Gross Margin (TTM) | EPS Growth (5Y) | Price |
|---|---|---|---|---|---|
TAKTakeda Pharmaceutical Company Limited American Depositary Shares (each representing 1/2 of a share of Common Stock) | 1.98x | -2.50% | 65.33% | 19.33% | $17.55 |
LLYEli Lilly & Co. | 13.45x | 44.70% | 83.04% | 27.59% | $919.90 |
JNJJohnson & Johnson | 5.82x | 7.87% | 67.95% | 14.90% | $230.69 |
ABBVABBVIE INC. | 5.97x | 8.57% | 71.62% | -2.88% | $203.71 |
MRKMerck & Co., Inc. | 4.51x | 1.31% | 78.55% | 21.23% | $117.10 |
AZNAstraZeneca PLC | 5.39x | 8.63% | 81.31% | 21.88% | $200.69 |
NVSNovartis AG | 4.87x | 8.91% | 75.82% | 15.26% | $150.99 |
NVONovo-Nordisk A/S | 3.74x | 6.43% | 80.98% | 20.66% | $40.46 |
ABTAbbott Laboratories | 3.71x | 6.59% | 56.50% | 8.20% | $96.00 |
PFEPfizer Inc. | 2.50x | -1.64% | 75.81% | -3.51% | $27.52 |
BMYBristol-Myers Squibb Co. | 2.52x | -0.22% | 72.63% | — | $59.13 |
About
Japan's largest pharmaceutical company with JPY 4.6 trillion in fiscal 2024 revenue. Takeda derives over 80% of sales from five core therapeutic areas: oncology, gastroenterology, neuroscience, rare diseases, and plasma-derived therapies. Geographic revenue is well-diversified across the US (over 50%), Japan (20%), and Europe/Canada (20%).